Health ❯ Healthcare

Adverse Effects

Treatment-Emergent Adverse Effects Drug Safety Treatment-Related Adverse Effects Medication Side Effects Cytokine Release Syndrome Safety Profiles Vaccine Side Effects Vaccine Safety Treatment-Related Adverse Events Gastrointestinal Issues

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

The ruling gives unfit, newly diagnosed patients a home-based alternative that still demands vigilant safety oversight.

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Mantle Cell Lymphoma

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Musk’s X Post on Vaccine Reaction Reignites Scrutiny of Covid Vaccines

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

3.1 Million Bottles of Store-Brand Eye Drops Recalled for Sterility Concerns

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

NEJM Study Pinpoints Adenoviral Protein Behind Rare Clots in AstraZeneca and J&J COVID Vaccines

NEJM Study Identifies Viral Protein and Antibody Mutation Behind Rare Vaccine‑Linked Clots

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show